Veneno Technologies

What Veneno Technologies does

Veneno Technologies Co., Ltd. is a Japan-based biotechnology company founded around 2020 and headquartered in Tsukuba, Ibaraki. It is a certified spinoff of the National Institute of Advanced Industrial Science and Technology (AIST) and operates with 1–10 employees. The company specializes in disulfide-rich peptides (DRPs) derived from animal venoms, which it redesigns through proprietary peptide engineering for therapeutic, agricultural, and animal-health applications.

The core technology stack comprises the DRP Drug Discovery Platform, described as the world's first end-to-end system for creating novel functional DRPs, and the Super Secrete Method, a proprietary high-yield production system using E. coli periplasm secretory expression. An in-house AI-based peptide sequence prediction model screens hundreds of millions of candidate compounds, with robotic automation of synthesis and evaluation. These capabilities are applied to three commercial vectors: DRP drug candidates targeting ion channels and GPCRs for autoimmune diseases and cancer, environmentally friendly peptide-based pesticides, and DRP-based animal therapeutics positioned as antibiotic alternatives.

Veneno operates a pure B2B licensing and joint development model with no direct product sales. Revenue streams are structured as preclinical-stage licensing of DRP drug candidates to pharmaceutical partners, joint research collaborations (including a three-way radiopharmaceutical program with Alpha Fusion and Mitsubishi Tanabe Pharma), and licensing of biomaterials for agrochemical and animal-feed use. To date, the company has raised approximately $2 million in seed funding (January 2022) from SBI Investment and Tsukuba Institute of Research, and has secured recognition through the BioLabs Masterclass cohort 2 acceleration program in 2026.

Name

Veneno Technologies

Legal name

Veneno Technologies Co., Ltd.

Website

https://veneno.jp

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Veneno Technologies is a Japan-based AIST spinoff biotech that develops and licenses disulfide-rich peptide (DRP) technologies derived from venom for drug discovery, agrochemicals, and animal health, serving pharmaceutical and agricultural companies through preclinical licensing and joint development agreements.

Ownership category

akta.pro rank

Product category

Peptide Drug Discovery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pesticide and Other Agricultural Chemical Manufacturing (32532)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

Keywords

• Peptide drug discovery
• Venom-derived peptides
• Biotechnology platform
• Agrochemical development
• Animal health therapeutics

Headquarters

HQ city

Tsukuba

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Licensing Revenue: Licensing out DRP drug candidates during the preclinical stage to pharmaceutical companies. The company develops drug candidates for autoimmune diseases and cancer in collaboration with pharma partners, generating revenue through licensing agreements.
2. Biomaterials Commercialization: Commercialization of biomaterials for use in pesticides and animal feed. Revenue generated from the sale and licensing of environmentally friendly peptide pesticides, animal therapeutics, and food ingredients.
3. Joint Research Collaboration: Revenue from joint research collaborations with pharmaceutical companies for specific drug development programs, such as the partnership with Alpha Fusion and Mitsubishi Tanabe Pharma for cancer radiopharmaceuticals.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Veneno Technologies is a Japan-based biotechnology company that develops and commercializes Disulfide-Rich Peptides (DRP) derived from animal venom for pharmaceutical, agricultural, and animal health applications. The company operates an end-to-end drug discovery platform that designs, synthesizes, and screens novel DRPs targeting ion channels and GPCRs, and licenses DRP drug candidates to pharmaceutical partners during the preclinical stage. It also develops environmentally friendly peptide-based pesticides and animal therapeutics as antibiotic alternatives.

Product overview

Veneno Technologies operates as a platform-based biotechnology company centered on Disulfide-Rich Peptides (DRP) derived from venom. The core technology stack comprises the DRP Drug Discovery Platform, which enables end-to-end creation and large-scale screening of functional peptides, and The Super Secrete Method, a proprietary high-yield production technology using E. coli periplasm expression. The company applies these platforms across multiple commercial vectors: therapeutic drug candidates for autoimmune diseases and cancer targeting ion channels and GPCRs, DRP-based agrochemicals for sustainable pesticides, and DRP-based animal health products as antibiotic alternatives. The peptide engineering technologies enhance peptide stability and selectivity, serving as the foundational capability underpinning all product lines.

Differentiator

Problem solved

Functional benefit

Products and services

• DRP Drug Discovery Platform World's first end-to-end technology platform that enables creation of novel functional disulfide-rich peptides (DRPs) for drug discovery, including large-scale screening and synthesis of DRPs tailored to specific target proteins. Used by pharmaceutical partners to develop novel therapies for diseases where small molecules and antibodies have struggled.
• DRP Drug Candidates for Autoimmune Diseases and Cancer Pipeline of disulfide-rich peptide drug candidates targeting ion channels and GPCRs for autoimmune diseases and cancer, developed jointly with pharmaceutical partners for licensing during the preclinical stage. Includes next-generation radiopharmaceuticals using astatine-211 labeling for precise cancer cell targeting.
• DRP-Based Agrochemicals (Peptide Pesticides) Environmentally friendly next-generation peptide pesticides that target only specific pests while protecting beneficial insects and ecosystems, offering sustainable agriculture solutions as alternatives to conventional chemical pesticides. Commercialized through licensing and joint development partnerships with agricultural and chemical companies.
• DRP-Based Animal Health Products DRP-based therapeutics for pets and livestock developed as alternatives to conventional antibiotics, addressing antibiotic-resistant bacteria and supporting disease care associated with the increasing longevity of companion animals and improving livestock productivity.

Quantifiable outcome

• Large-scale screening capability for disulfide-rich peptides with AI-driven evaluation of hundreds of millions of candidate compounds
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• Molmir Inc.coreStrategic or Co-development Partner · 25 November 2025Business alliance to build a new commercialization model ensuring academic drug discovery does not end at the research stage. Molmir has strong expertise in identifying and refining drug discovery seeds originating from academia. This partnership addresses the challenge of bringing academic discoveries to market.
• Alpha Fusion Inc.majorStrategic or Co-development Partner · 10 July 2025Joint research collaboration launched with Alpha Fusion and Mitsubishi Tanabe Pharma to develop innovative cancer therapeutics. The collaboration focuses on developing next-generation radiopharmaceuticals using proprietary peptide technologies, specifically astatine-211-labeled radiopharmaceuticals that precisely target cancer cells.
• Mitsubishi Tanabe Pharma CorporationmajorStrategic or Co-development Partner · 10 July 2025Three-way joint research collaboration with Alpha Fusion and Veneno Technologies to develop innovative cancer therapeutics using proprietary peptide technologies. Focus on next-generation radiopharmaceuticals targeting cancer cells precisely, specifically astatine-211-labeled radiopharmaceuticals.
• AIST (National Institute of Advanced Industrial Science and Technology)coreStrategic or Co-development PartnerVeneno Technologies is certified as an AIST-spinoff venture. The company builds on fundamental research cultivated at AIST and maintains IP and patent strategy in collaboration with AIST. The partnership provides access to government grants and strengthens licensing model through patent applications.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Bicycle Therapeutics: Clinical-stage biotechnology company developing bicyclic peptide therapeutics (bicycles) for oncology and other diseases. Directly comparable to Veneno as a peptide-based drug discovery platform with a similar B2B licensing and partnership model.
• PeptiDream: Japan-based peptide discovery company using its Peptide Discovery Platform System (PDPS) to generate constrained and modified peptides for pharmaceutical partners. The closest geographic and technical peer to Veneno, with a similar licensing-heavy business model.
• Crinetics Pharmaceuticals: Clinical-stage biotech developing peptide therapeutics for endocrine diseases and endocrine-related tumors. Comparable as a peptide drug discovery company targeting GPCRs and similar challenging targets.
• Protagonist Therapeutics: Clinical-stage biopharmaceutical company developing peptide-based therapeutics for hematology, hematologic malignancies, and inflammatory diseases. Directly comparable as a constrained/engineering-focused peptide platform.
• Vestaron: US-based agricultural biotech company developing peptide-based bioinsecticides derived from spider venom as alternatives to chemical pesticides. The most direct competitor to Veneno's agrochemical DRP-pesticide business.
• Pepscan: Netherlands-based company specializing in peptide discovery services and constrained peptide technology (CLIPS) for therapeutic and diagnostic applications. Comparable as a peptide discovery platform serving pharma partners.

Broad incumbents

• Zealand Pharma: Denmark-based clinical-stage peptide therapeutics company with approved products and a broad pipeline across metabolic and gastrointestinal diseases. Comparable as a peptide platform company, though larger and more clinically advanced.

Emerging players

• Sapience Therapeutics: Clinical-stage biotechnology company developing peptide therapeutics targeting intracellular protein-protein interactions in oncology. Comparable as an emerging peptide platform targeting previously difficult-to-drug biology.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/veneno-technologies-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veneno Technologies